Lemonaid Health, a subsidiary of 23andMe Holding (ME), is now offering Petros Pharmaceuticals, Inc.’s (PTPI), prescription erectile dysfunction medication STENDRA through its telehealth platform. Working directly with STENDRA manufacturer Petros Pharmaceuticals, Lemonaid Health is able to offer the fast-acting ED medication at improved pricing. With one in 10 men estimated to have ED at some point in their lifetime1, Lemonaid Health clinicians are able to evaluate and prescribe patients a variety of ED medications at various price points and doses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ME:
- 23andMe to Report Q4 and Full Year FY2024 Financial Results
- 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Petros Pharmaceuticals expands online distribution for prescription STENDRA
- M&A News: 23andMe (NASDAQ:ME) Soars on CEO’s Take-Private Intention
- 23andMe Forms Special Committee for Strategic Governance
Questions or Comments about the article? Write to editor@tipranks.com